Monopar Therapeutics
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $0.0 | $0.0 | — | — | — |
| Operating income | -$16.7 | -$16.2 | -$8.8 | -$10.5 | -$9.1 |
| Net income | -$13.7 | -$15.6 | -$8.4 | -$10.5 | -$9.1 |
| Cash Flow Statement | |||||
| Share repurchases | $35.0 | $0.0 | — | — | — |
Shares outstanding 6.7M · Free float 78.0%
Annual filing data through FY ended December 31, 2025; float as of September 18, 2026.